Supporting the

Neuroendocrine Cancer Community

Update on Lutathera® announcement by Novartis

May 6, 2022

Some of you may have seen the announcement, by Novartis, that there is a temporary, voluntary suspension of radioligand therapy production:

May 5th 2022 — Novartis today announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey. 

As a result, the company is temporarily suspending delivery of:

  • Lutathera® (USAN: lutetium Lu 177 dotatate; INN: lutetium (177Lu) oxodotreotide) in the US and Canada 


  • 177Lu-PSMA-617 (INN: lutetium (177Lu) vipivotide tetraxetan), marketed as Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) in the US. 

In addition, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, and Lutathera clinical trials in the US and Canada.

Novartis radioligand therapy production site in Zaragoza, Spain is not suspended – although there may be some delays in supply.

Full press release here

NCUK have spoken with Novartis this morning and been assured that UK supply will be largely unaffected, in that UK supply will continue, but there may be some slight delays.